- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01890772
Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1
A Pilot Trial of the Safety and Efficacy of Telaprevir +Peginterferon +Ribavirin +Vitamin D3 Among Treatment-naive Veterans Infected With Genotype 1 Hepatitis C Virus
This study is for people who have been diagnosed with chronic hepatitis C, specifically those who have a certain type of the virus, genotype 1, and who have not yet received treatment for hepatitis C. This pilot study is designed to test whether the addition of vitamin D, to the three drugs (Incivek (telaprevir), Pegasys (peginterferon alfa-2a), and ribavirin) that are approved by the Food and Drug Administration (FDA) for the treatment of hepatitis C, can help eliminate the HCV from the body. Currently, doctors are unsure if the addition of vitamin D to prescribed hepatitis C therapy will have any effects on how the body clears the virus.
Once enrolled, participants will be randomly assigned (like flipping a coin) to receive telaprevir + peginterferon alfa-2a + ribavirin + vitamin D3 (treatment group) or telaprevir + peginterferon alfa-2a + ribavirin (control group). A total of 80 participants, of all races/ethnicities, will be included in this study, at 5 to 10 VA hospital study sites (10 - 20 participants/site).
Participants assigned to the treatment group will begin a lead-in phase where they will receive 5,000 IU of vitamin D3 per day. Every two weeks during the lead-in phase, participants will be tested to determine the Vitamin D level in their blood, as well as other tests, including HCV RNA (to determine the amount of virus present) and calcium levels. Once an adequate level of Vitamin D is detected in participants' blood, participants will begin treatment with telaprevir + peginterferon alfa-2a + ribavirin + vitamin D3 (15,000 IU/week) for 12 weeks.
Participants randomized to the control group will immediately begin treatment with telaprevir + peginterferon alfa-2a + ribavirin for 12 weeks. At the end of Week 12 the participants' involvement in the study will be complete.
Adverse events and effects of vitamin D3 will be obtained by assessing participants' medical history, physical examination, and blood tests at clinic visits. HCV RNA will be assessed at Screening, Day 1, Week 2, 4, 8 and 12.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Fase
- Fase 2
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
California
-
Long Beach, California, Forente stater, 90822
- VA Long Beach Healthcare System
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55417
- Minneapolis VAHCS
-
-
Missouri
-
Kansas City, Missouri, Forente stater, 64128
- Kansas City VA Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Philadelphia VA Medical Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Chronic Hepatitis C genotype 1 infection
- Treatment naïve
- Age >18 years
- Agree to genetic testing
Exclusion Criteria:
- Liver disease other than from hepatitis C
- HCV infection with mixed genotypes
- Decompensated liver disease
- AFP>100ng/ml.
- Known HIV infection
- Serum 25(OH)D less than 12ng/ml or greater than 30ng/ml
- Regular vitamin D supplement use
- Regular calcium supplement use
- Refusal to abstain from vitamin D supplementation
- Current or past history of kidney stones
- Current use of any of the prohibited medications listed in section 5.5 and the INCIVEK® package insert.
- Need for therapeutic vitamin D or calcium (e.g. treatment for osteoporosis, osteomalacia, hyperparathyroidism etc.), in the opinion of the investigator
- Significant substance abuse within the past 6 months,
- Suicidal attempt in the past 10 years or suicidal ideation in past 3 months, or any other psychiatric condition that the investigator deems would make a subject unsuited for treatment with peginterferon or ribavirin.
- Confirmed or suspected malignancy, or history of malignancy within the past 3 years (except treated basal cell carcinoma of the skin or in situ carcinoma of the uterine cervix)
- Any autoimmune disease not easily controlled (in the opinion of the investigator)
- Any condition resulting in malabsorption (
- Poorly controlled thyroid disorder, or diabetes mellitus (HbA1c > 9)
- Glomerular diseases (e.g., glomerulosclerosis or glomerulonephritis) associated with a serum creatinine >1.5 times the upper limit of normal
- Current or history of any clinically significant cardiac abnormalities/dysfunction (eg, angina, congestive heart failure, myocardial infarction, pulmonary hypertension, complex congenital heart disease, cardiomyopathy, significant arrhythmia) including current uncontrolled hypertension or history of use of antianginal agents for cardiac conditions (Inclusion will be considered if clearance by a cardiologist is obtained.)
- Receipt of an investigational drug within the past 30 days
- Females who have a positive pregnancy test at the time of screening, are breastfeeding or who anticipate pregnancy within the next 18 months, or men with pregnant partners
- Lack of agreement from subject to use two forms of acceptable contraception
- History or other evidence of any significant illness which, in the opinion of the investigator, would make the patient, unsuitable for the study
- Laboratory Exclusions
Hemoglobin: <12gm/dl male or female
Neutrophil: <1,200/mm3
Platelets: <90,000/mm3
INR: >1.5
Albumin: <3.2gm/dl
Total Bilirubin: >2.0mg/dl
HbA1c: >9.5%
Serum Creatinine: >1.5 times the upper limit of normal
Serum Calcium Within local laboratory normal range
Parathyroid hormone (PTH) <10 or >55 pg/mL
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: VitD+telaprevir+peginterferon+ribavirin
Participants randomized to the treatment group will receive 5,000IU/day of vitamin D3 during the lead-in phase.
When the serum 25(OH)D level is ≥35ng/ml the participant will begin telaprevir + vitamin D3 (15,000IU/week) + peginterferon alfa-2a (180ug/week) + weight based ribavirin treatment.
|
Andre navn:
Andre navn:
|
Aktiv komparator: Telaprevir + Peginterferon + Ribavirin
Participants randomized to the control group immediately begin treatment with telaprevir + 180ug of peginterferon alfa-2a (Pegasys) per week and either weight based ribavirin.
|
Andre navn:
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
HCV RNA
Tidsramme: 4 weeks
|
Hepatitis C virus Ribonucleic Acid identifies the presence of Hepatitis C in the blood
|
4 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
adverse event profile
Tidsramme: 12 weeks
|
Cumulative record of unanticipated or unintended medical occurrences, not necessarily related to the study treatment.
|
12 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Timothy R Morgan, MD, Veterans Affairs Long Beach Healthcare
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i fordøyelsessystemet
- RNA-virusinfeksjoner
- Virussykdommer
- Infeksjoner
- Blodbårne infeksjoner
- Smittsomme sykdommer
- Leversykdommer
- Flaviviridae-infeksjoner
- Hepatitt, viral, menneskelig
- Enterovirusinfeksjoner
- Picornaviridae-infeksjoner
- Hepatitt
- Hepatitt A-virus
- Hepatitt C
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Anti-infeksjonsmidler
- Antivirale midler
- Antimetabolitter
- Mikronæringsstoffer
- Vitaminer
- Bone Density Conservation Agents
- Ribavirin
- Peginterferon alfa-2a
- Vitamin d
Andre studie-ID-numre
- 1217
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Hepatitt C
-
Dokuz Eylul UniversityEge UniversityFullførtMMP9 | TIMP1 | MMP9 -1562 C/T | TIMP1 372 T/CTyrkia
-
Tripep ABInovio PharmaceuticalsUkjentKronisk hepatitt C virusinfeksjonSverige
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsTilbaketrukketKronisk hepatitt C virusinfeksjonIsrael
-
Hadassah Medical OrganizationUkjentKronisk hepatitt C virusinfeksjonIsrael
-
Johann Wolfgang Goethe University HospitalFullført
-
Beni-Suef UniversityFullførtٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin og HCV genotype 4-infiserte egyptisk erfarne deltakereKronisk hepatitt C virusinfeksjonEgypt
-
University College CorkDupont Applied BiosciencesRekruttering
-
Trek Therapeutics, PBCFullførtKronisk hepatitt C | Hepatitt C genotype 1 | Hepatitt C (HCV) | Hepatitt C viral infeksjonForente stater, New Zealand
-
Trek Therapeutics, PBCFullførtKronisk hepatitt C | Hepatitt C (HCV) | Hepatitt C genotype 4 | Hepatitt C viral infeksjonForente stater
-
Meir Medical CenterFullførtUtvikle ny teknikk for å måle C/D-forhold fra digitale stereooptiske plater | Intraobserver reproduserbarhet av C/D-målinger | Interobservatørvariabilitet av C/D-målinger
Kliniske studier på Vitamin d
-
Nutrition Institute, SloveniaSlovenian Research Agency; Higher School of Applied Sciences (VIST); Valens...FullførtVitamin D-mangelSlovenia
-
Khon Kaen UniversityHar ikke rekruttert ennå
-
Fundación Cardiovascular de ColombiaUniversidad Industrial de Santander; Farma de Colombia SAFullførtVitamin D-mangel | Overvekt og fedme | Overvektige ungdomColombia
-
USDA, Western Human Nutrition Research CenterFullført
-
University of ViennaUkjent
-
University Hospital, Basel, SwitzerlandFullført
-
Fundación Pública Andaluza para la gestión de la...FullførtHematopoetisk stamcelletransplantasjonSpania
-
University of AarhusHar ikke rekruttert ennåSykdommer i immunsystemet | Vekst | Barneutvikling | Vitamin D-tilskudd
-
Pauls Stradins Clinical University HospitalFullført
-
University of TromsoPublic Dental Service Competence Center of Northern NorwayHar ikke rekruttert ennåBetennelse | Periodontitt | Periodontale sykdommer | Vitamin d | Periodontal betennelse | Inflammasjon i tannkjøttetNorge